微轴流泵治疗老年心源性休克患者:年龄是否影响获益?
该研究为DanGer Shock试验的二次分析,纳入355例STEMI相关心源性休克患者,随机接受mAFP(Impella CP)联合标准治疗或单纯标准治疗。按年龄四分位分析显示,年龄最高四分位组180天死亡调整OR为7.85(95%CI 3.37-19.2)。在<77岁患者中mAFP降低180天死亡率(OR 0.45,95%CI 0.28-0.73,P=0.001),≥77岁患者未见获益(OR 1.52,95%CI 0.57-4.08,P=0.40),交互P=0.028。
要点
- 年龄越高,STEMI相关心源性休克患者180天死亡率越高(从31%升至73%,log-rank P<0.001)。
- 年龄<77岁患者接受mAFP可降低180天死亡率(OR 0.45,95%CI 0.28-0.73)。
- 年龄≥77岁患者未观察到mAFP的生存获益(OR 1.52,95%CI 0.57-4.08)。
核心结论
- 老年STEMI相关心源性休克患者死亡率高,可能无法从常规mAFP治疗中获得与年轻患者相同的生存获益。
- 将年龄纳入患者选择因素可能提高该疗法的总体获益。
研究设计与样本
- DanGer Shock试验的探索性二次分析,为国际、多中心、开放标签随机对照试验。
- 共纳入355例成人STEMI相关心源性休克患者,随机接受mAFP(Impella CP)联合标准治疗或单纯标准治疗。
- 主要终点为180天全因死亡率,按年龄和干预措施进行分析。
主要发现
- 年龄四分位组中位年龄分别为54岁(Q1-Q3:31-59)、65岁(Q1-Q3:60-69)、73岁(Q1-Q3:70-76)和81岁(Q1-Q3:77-92)。
- 各年龄组随机化时的血压、乳酸水平、左心室射血分数或休克严重程度无差异。
- 180天死亡率从最低至最高年龄四分位组依次为31%、47%、61%和73%(log-rank P<0.001)。
- 最高四分位组相比最低四分位组180天死亡调整OR为7.85(95%CI:3.37-19.2;P<0.001)。
- 年龄<77岁患者中,mAFP组180天死亡率降低(OR:0.45;95%CI:0.28-0.73;P=0.001);年龄≥77岁患者中OR为1.52(95%CI:0.57-4.08;P=0.40),交互P=0.028。
关键数值与推荐
- 年龄<77岁:mAFP联合标准治疗可降低180天死亡率(OR 0.45,95%CI 0.28-0.73,P=0.001)。
- 年龄≥77岁:mAFP未见生存获益(OR 1.52,95%CI 0.57-4.08,P=0.40),交互P=0.028。
- 预测死亡风险在约77岁之前标准治疗组更高,之后mAFP组更高(P=0.20)。
临床怎么用
- 对于STEMI相关心源性休克患者,选择mAFP治疗时应考虑年龄因素。
- 年龄<77岁患者可能从mAFP联合标准治疗中获益更多。
- 年龄≥77岁患者常规使用mAFP的获益不确定,需个体化评估。
局限性
- 本研究为探索性二次分析,结果需谨慎解读。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether age impacts the recently demonstrated survival benefit of microaxial flow pump (mAFP) treatment in patients with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock (CS) is unknown. OBJECTIVES: The purpose of this study was to assess the impact of age on mortality and complication rates in patients with STEMI-related CS randomized to standard care or mAFP on top of standard care. METHODS: This is a secondary analysis of the Danish-German Cardiogenic Shock (DanGer Shock) trial, an international, multicenter, open-label trial, in which 355 adult patients with STEMI-related CS were randomized to receive an mAFP (Impella CP) plus standard care or standard care alone. The primary outcome of 180-day all-cause mortality is analyzed according to age and intervention. RESULTS: From lowest to highest age quartile, the median ages (range) were 54 years (Q1-Q3: 31-59 years), 65 years (Q1-Q3: 60-69 years), 73 years (Q1-Q3: 70-76 years), and 81 years (Q1-Q3: 77-92 years). There were no differences in blood pressure, lactate level, left ventricular ejection fraction, or shock severity at randomization across age groups. Mortality increased from lowest to highest quartile (31%, 47%, 61%, and 73%, respectively; log-rank P < 0.001), with an adjusted OR for death at 180 days of 7.85 (95% CI: 3.37-19.2; P < 0.001) in the highest quartile compared to the lowest. The predicted risk of mortality was higher in the standard-care group until approximately 77 years, after which the predicted risk became higher in the mAFP group (P = 0.20). In patients <77 years, a reduced 180-day mortality was observed in patients randomized to the mAFP (OR: 0.45; 95% CI: 0.28-0.73; P = 0.001), opposed to patients aged ≥77 years (OR: 1.52; 95% CI: 0.57-4.08; P = 0.40), P for interaction = 0.028. Complications were more frequent in the mAFP group, but there were no apparent differences in incidence of complications across all ages. CONCLUSIONS: This exploratory secondary analysis of the DanGer Shock trial demonstrates that older patients with STEMI-related CS experience high mortality and may not attain the same benefit from routine treatment with an mAFP as younger patients. Incorporating age as a factor in patient selection may enhance the overall benefit of this therapy. (Danish Cardiogenic Shock Trial [DanShock]; NCT01633502).
引用
- Klein, Beske, Hassager, et al. Treating Older Patients in Cardiogenic Shock With a Microaxial Flow Pump: Is it DANGERous? J Am Coll Cardiol. 2024. PMID: 39551167. doi:10.1016/j.jacc.2024.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。